Median OS Reaches 25.3 Months: Amgen Announces Updated Clinical Data for Tarlatamab in ES-SCLC at WCLC 2025; BeiGene Holds Partial Rights

Recently, Amgen announced at the WCLC conferenceTaladotinib（Tarlatamab）In combination with PD-L1 monoclonal antibody for extensive-stage small cell lung cancer（ES-SCLC）First-line maintenance therapy after chemotherapyTheStage IbClinicalTheUpdates on Safety and Survival Period（DeLLphi-303，NCT05361395）。

DeLLphi-303 is a non-randomized, open-label Phase Ib clinical study. The subjects are ES-SCLC patients who have completed 4-6 cycles of first-line platinum-etoposide combined with PDL1 monoclonal antibody treatment without disease progression.

Within 8 weeks after the start of the last cycle of chemotherapy combined with immunotherapy, the patient receivedTarlatamab(10mg, once every two weeks intravenously)Combined with Atezolizumab(1680mg, once every four weeks by intravenous injection)Or Durvalumab(1500mg, once every four weeks intravenously), until disease progression. The primary endpoint isAdverse Event, Secondary endpoints includeOverall Survival（OS）AndProgression-Free Survival（PFS）。

The study has a total of88 subjectsAcceptedTaladotinib combined with atezolizumab or durvalumab for treatment.The median follow-up time from the start of maintenance therapy was 18.4 months.TarlatThe median exposure time for monoclonal antibodies was 35 weeks.

The most commonTaratoMonoclonal antibody-related adverse events are cytokine release syndrome.（CRS）, with an incidence rate of 56%, mainly Grade 1. Immune effector cell-associated neurotoxicity syndrome occurred in 6% of patients. Treatment-related adverse events decreased over time.

Median OS was 25.3 months(95% CI, 20.3-not reached), with a median PFS of 5.6 months（95% CI，3.5-9.0）。

Source: WCLC 2025

Tarlatuzumab in combination with anti-PD-L1 therapy demonstrated acceptable safety, good long-term tolerability, and unprecedented OS.

Cover Source:Corporate Logo

Disclaimer:This article is for information sharing only and does not represent the position or viewpoint of Insight. It does not recommend or introduce any treatment plans. If necessary, please consult and contact正规医疗机构.

Editor: Crescent

PR Article Coordination: WeChat insightxb